Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the two major
types of chronic liver disease worldwide. Inflammatory processes play key roles in the …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …

Background TP53 mutation is the most common mutation in hepatocellular carcinoma
(HCC), and it affects the progression and prognosis of HCC. We investigated how TP53 …

Purpose: To evaluate the mechanisms of how therapeutic upregulation of the transcription
factor, CCAAT/enhancer-binding protein alpha (C/EBPα), prevents tumor progression in …

In association with the pandemic spreading of obesity and metabolic syndrome, the
prevalence of NAFLD‐related HCC is increasing almost exponentially. In recent years, many …

Simple Summary Hepatocellular carcinoma is one of the most common cancers in the world
with increasing incidence. In advanced stages, according to the Barcelona Clinic Liver …

Background and Aims Targeting costimulatory receptors with agonistic antibodies is a
promising cancer immunotherapy option. We aimed to investigate costimulatory receptor …

Summary Background and Aims Phase III trials have established atezolizumab plus
bevacizumab as the novel standard of care for patients with unresectable hepatocellular …

Hepatocellular carcinoma (HCC) constitutes most primary liver cancers and is one of the
most lethal and life-threatening malignancies globally. Unfortunately, a substantial …

Simple Summary The cytotoxic T cell response against hepatocellular carcinoma antigens is
exhausted and fails in its task of deleting tumoral cells. These cells are featured by the …